MERRF Mutation A8344G in a Four-Generation Family without Central Nervous System Involvement: Clinical and Molecular

Michela Ripolone1, Simona Zanotti1, Laura Napoli1

  • 1Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Insights

This study investigates the A8344G mitochondrial DNA mutation, typically causing MERRF (myoclonus epilepsy with ragged-red fibers). Despite carrying the mutation, this family shows late-onset, non-neurological symptoms, suggesting protective genetic factors.

Area of Science:

  • Genetics
  • Neurology
  • Mitochondrial Biology

Background:

  • Mitochondrial disorders are often inherited and can lead to severe multisystemic symptoms.
  • The A8344G mutation in mitochondrial DNA (mtDNA) is classically associated with MERRF (myoclonus epilepsy with ragged-red fibers).

Observation:

  • A 53-year-old man presented with incidental hyperckemia, exhibiting diabetic and lipoma history, similar to his deceased mother.
  • Muscle biopsy revealed COX-negative and ragged-red fibers, indicative of mitochondrial dysfunction.
  • Genetic analysis confirmed the A8344G mtDNA mutation in the proband and his two sisters.

Findings:

  • The family, spanning four generations, carries the A8344G mutation but displays atypical, late-onset phenotypes without central nervous system (CNS) involvement.
  • Despite the known association of this mutation with MERRF, CNS manifestations were absent in this lineage.
  • Low mutational load and potential regulatory genetic factors may explain the spared CNS and delayed symptom onset.

Implications:

  • This case challenges the typical MERRF phenotype presentation and highlights the variability of mitochondrial disease expression.
  • The findings suggest the existence of protective genetic mechanisms influencing mitochondrial segregation and replication, preventing severe organ dysfunction.
  • Further research into these regulatory pathways could offer new therapeutic targets for mitochondrial disorders.